Category Archives: Corporate

New Inversion Rules Test Pending Deals, WSJ Reports

The U.S. Treasury Department’s latest attempt at stopping corporate inversions last week spelled doom for Pfizer Inc.’s (New York City) $150 billion attempted takeover of Allergan PLC (Dublin IRL)–what would… Read more »